Assembly Biosciences(ASMB.US)

Last Updated 19:00:00 ET
longbridge loading

Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference

Market Beat·
US
ASMB
+0.91%
Market Beat·
US
ASMB
+0.91%

Analyst Reiterates Buy on Assembly Biosciences, Maintains $50 Price Target Amid Pipeline Progress and 2028 Cash Runway

Tip Ranks·
US
ASMB
+0.91%
Tip Ranks·
US
ASMB
+0.91%

Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026 | ASMB Stock News

StockTitan·
US
ASMB
+0.91%
StockTitan·
US
ASMB
+0.91%

Assembly Biosciences GAAP EPS of -$0.54 beats by $0.03, revenue of $8.21M beats by $1.26M

businessinsider·
US
ASMB
+0.91%
businessinsider·
US
ASMB
+0.91%

Assembly Biosciences | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 8.213 M

Earnings Watch·
US
ASMB
+0.91%
Earnings Watch·
US
ASMB
+0.91%

Marvel Biosciences Announces Closing of Convertible Debenture Offering | MBCOF Stock News

StockTitan·
US
ASMB
+0.91%
US
LEXX
+4.14%
US
MBX
+1.15%
StockTitan·
US
ASMB
+0.91%
US
LEXX
+4.14%
US
MBX
+1.15%

Marvel Biosciences Wins Non-Dilutive Backing for MB-204 Phase I Trial

Tip Ranks·
US
XBI
+0.81%
US
PBE
+0.35%
US
ARKG
+3.35%
Tip Ranks·
US
XBI
+0.81%
US
PBE
+0.35%
US
ARKG
+3.35%

Assembly Biosciences (ASMB) Gets a Buy from Guggenheim

Tip Ranks·
US
ASMB
+0.91%
Tip Ranks·
US
ASMB
+0.91%
© 2026 Longbridge｜Disclaimer